Analysis of Percutaneous Ablations for Cancer Treatment

Prospective Analysis of Percutaneous Ablations for Cancer Treatment

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01563679

Enrollment

Registered

2012-03-27

Start date

2012-02-29

Completion date

2014-01-31

Last updated

2014-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

cancer, locoregional therapies, RFA, Cryoablation, Microwave ablation, chemical ablation, Irreversible electroporation

Brief summary

This is a study involving patients with cancer who are referred by their treating physician for percutaneous locoregional therapies. Patient's clinical and radiology findings, pathology findings, survival, treatment responses, and complications after their locoregional therapy will be studied.

Detailed description

The efficacy of the percutaneous and transarterial treatments for solid tumors will be studied. Prospective study on patients who receive percutaneous locoregional therapies, including radiofrequency ablation (RFA), cryoablation, microwave ablation, IRE and chemical ablation for treatment of cancer will be performed. Preoperative clinic chart, procedure note, postoperative chart, pre- and post-operative CT, MRI or Ultrasound, angiographic findings, biopsy results and pathologic findings, will be reviewed. Patient survival, treatment responses, complications after the therapy will be collected from clinic visits and clinical encounters. Patient overall performance status before and after procedures will be assessed using the Quality of Life questionnaire (SF-36™ Health Survey).

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* 18yrs of age * Cancer diagnosis * Candidate for Locoregional therapy * Willingness to sign informed consent

Exclusion criteria

* Unable to sign informed consent * Patients not eligible for locoregional therapies

Design outcomes

Primary

Measure	Time frame	Description
Effect of percutaneous and transarterial treatments for cancer in quality of life	1 year	Patients will complete the QOL questionnare during their follow up visits after procedure. 1 month, 3 months, 6 months and 1 year.

Secondary

Measure	Time frame	Description
response rate to percutaneous and transarterial treatment for cancer	1 month, 3 months, 6 months, 1 year.	Patients will be followed up 1, 3, 6 and 1year intervals after procedure.

Countries

United States

Outcome results